MLTX MoonLake Immunotherapeutics
Healthcare$18.36+0.00%OpenMarket Cap: $1.35B
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
5.10
P/S
0.00
EV/EBITDA
-4.58
DCF Value
$4.08
FCF Yield
-16.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-85.6%
ROA
-64.2%
ROIC
-75.3%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | -Infinity% | $-70.0M | $-69.7M | $— | — |
| Q4 null | $0.00 | -Infinity% | $-65.2M | $-62.4M | $— | — |
| FY null | $0.00 | -Infinity% | $-244.8M | $-227.3M | $— | — |
| Q3 null | $0.00 | NaN% | $-71.4M | $-69.7M | $— | — |
| Q2 null | $0.00 | -Infinity% | $-60.7M | $-55.2M | $— | — |
| Q1 null | $0.00 | NaN% | $-47.5M | $-39.9M | $— | — |
| Q4 null | $0.00 | NaN% | $-49.6M | $-45.6M | $— | — |
| FY null | $0.00 | NaN% | $-143.1M | $-118.9M | $— | — |
| Q3 null | $0.00 | -Infinity% | $-43.1M | $-35.4M | $— | — |
| Q2 null | $0.00 | NaN% | $-30.6M | $-24.3M | $— | — |
| Q1 null | $0.00 | NaN% | $-19.8M | $-13.7M | $— | — |
| Q4 2023 | $0.00 | NaN% | $-15.0M | $-7.4M | $-0.12 | — |